NovaBridge Biosciences (NBP) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.7x

Market Cap

$208.80M

MomentumView details →

1D Return

+0.00%

YTD Return

−55.03%

RSI (14)

46.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.7x

Market Cap

$208.80M

RSI (14)

46.9

MomentumView details →

1D Return

+0.00%

YTD Return

−55.03%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−60.22%

ROA (TTM)

−53.39%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+96.41%

EBITDA YoY

+89.18%

EarningsView details →

EPS (Actual)

−$0.22

EPS Surprise

−2660.35%

Beats (12Q)

3/12

Next Q EPS Est

−$0.54

Avg Surprise (4Q)

−1055.97%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

8.09x

Quick Ratio

8.09x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−19.88M

Op. CF (TTM)

−1.45M

Next earningsNov 12, 2026 →

Latest newsMore news →

NovaBridge Biosciences reported financial results for the six months ended June 30, 2026, and provided a business update on pipeline momentum and strategic execution.15d ago

Similar companies

Nkarta, Inc.NKTX Oramed Pharmaceuticals Inc.ORMP Precision BioSciences, Inc.DTIL Minerva Neurosciences, Inc.NERV Corbus Pharmaceuticals Holdings, Inc.CRBP PepGen Inc.PEPG Find similar companies →

Latest newsMore news →

NovaBridge Biosciences reported financial results for the six months ended June 30, 2026, and provided a business update on pipeline momentum and strategic execution.15d ago